Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

The statement also said, in part, that "robust data" supporting Wegovy's "meaningful and unique benefits continue to grow" and that in addition to "offering significant and sustained weight loss ...

INDIANAPOLIS, Indiana: Eli Lilly's obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk's Wegovy in the first direct comparison of the two blockbuster medications, ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025. (AP Photo/JoNel Aleccia) ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...

A new study shows Zepbound beats Wegovy for weight loss.

Those on Wegovy lost about 33 pounds. That translated to a loss of about 20% of body weight for Zepbound users, compared to nearly 14% for Wegovy users. What's more, waist size also shrank by an ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's (NOVOb.CO), opens new tab Wegovy across five weight-loss targets such as ...

Novo Nordisk told Reuters in a statement that a similar dose of Wegovy led to greater weight loss in a 2021 trial and one earlier this year than what was observed in the recent study. The company ...